Human CGRP1 ELISA Kit (Colorimetric)

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-75259

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NBP2-75259
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Sample Type & Volume Required Per Well

Serum, plasma and other biological fluids (100 uL)

Sensitivity

9.38 pg/mL

Assay Range

15.63 - 1000 pg/mL

View all CGRP1 ELISA Kits »

Product Specifications

Assay Type

Sandwich-ELISA

Kit Type

ELISA Kit (Colorimetric)

Reactivity

Human

Specificity

This kit recognizes Human CGRP1 in samples. No significant cross-reactivity or interference between Human CGRP1 and analogues was observed.

Precision

Intra-Assay Precision (Precision within an assay) CV% < 5.35%

Inter-Assay Precision (Precision between assays) CV% < 5.16%

Recovery for Human CGRP1 ELISA Kit (Colorimetric)

Recovery

87-105%

Linearity

Human CGRP1 ELISA Kit (Colorimetric)

Scientific Data Images for Human CGRP1 ELISA Kit (Colorimetric)

Human CGRP1 ELISA Kit (Colorimetric)

ELISA: Human CGRP1 ELISA Kit (Colorimetric) [NBP2-75259] -

ELISA: Human CGRP1 ELISA Kit (Colorimetric) [NBP2-75259] - Standard Curve Reference

Kit Contents for Human CGRP1 ELISA Kit (Colorimetric)

  • Biotinylated Detection Ab Diluent
  • Concentrated Biotinylated Detection Ab (100x)
  • Concentrated HRP Conjugate (100x)
  • Concentrated Wash Buffer (25x)
  • HRP Conjugate Diluent
  • Micro ELISA Plate (Dismountable)
  • Plate Sealer
  • Product Manual
  • Reference Standard
  • Sample Diluent
  • Stop Solution
  • Substrate Reagent

Preparation and Storage

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Storage of components varies. See protocol for specific instructions.

Background: CGRP1

Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuropeptide that functions as a vasodilator, has an important role in pain pathways, and has become a target for migraine treatment (1). The CGRP peptide is characterized by an N-terminal disulfide bond, an alpha-helical structure than plays a role in binding affinity, and an amine C-terminal (1,2). CGRP exists in alpha- and beta-isoforms encoded by genes CALCA (CALC I) and CALCB (CALC II), respectively (1,2). alphaCGRP and betaCGRP only differ by three amino acids, have greater than 90% homology, and each peptide has a theoretical molecular weight of ~3.8 kDa (1,2). alphaCGRP is the predominant peptide form and is expressed in regions of the central and peripheral nervous system, including sensory fibers and the trigeminal ganglia (1,2). Other members of the CGRP gene family includes adrenomedullin, and adrenomedullin 2 (intermedin), amylin, and calcitonin (1,2). When CGRP is released from nerve fibers and blood vessels, it binds a CGRP receptor complex (1-3). The receptor consists of G-protein coupled receptor calcitonin-like receptor (CLR) that is associated with an accessory protein receptor activity-modifying protein (RAMP) (2,3).

Signaling of CGRP and its receptor are involved in vasodilation, neurogenic inflammation, and peripheral sensitization of nociceptors, all of which relate to migraine pathophysiology (2-3). Studies have found that CGRP is both released during migraines and can also induce migraines (3-5). Under normal conditions CGRP levels are typical and neurotransmission is relative; however, migraine triggers including light and sound can increase CGRP levels, enhance neurotransmission, and alter the pain and sensory aversions associated with migraines (2). Given its role, CGRP and its receptor have been the target of many migraine therapeutics including small molecule agonists called gepants and monoclonal antibodies (3-5). Ubrogepant and Rimegepant, two small molecule CGRP receptor agonists, have been FDA approved while another agonist, Atogepant, is ongoing in clinical trials (3,5). Additionally, four monoclonal antibodies against either CGRP or its receptor that are used to block signaling have been FDA approved: Eptinezumab, Fremanezumab, Galcanezumab, and Erenumab (3-5).

References

1. Russell, F. A., King, R., Smillie, S. J., Kodji, X., & Brain, S. D. (2014). Calcitonin gene-related peptide: physiology and pathophysiology. Physiological reviews, 94(4), 1099-1142. https://doi.org/10.1152/physrev.00034.2013

2. Russo A. F. (2015). Calcitonin gene-related peptide (CGRP): a new target for migraine. Annual review of pharmacology and toxicology, 55, 533-552. https://doi.org/10.1146/annurev-pharmtox-010814-124701

3. Wattiez, A. S., Sowers, L. P., & Russo, A. F. (2020). Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting. Expert opinion on therapeutic targets, 24(2), 91-100. https://doi.org/10.1080/14728222.2020.1724285

4. Deen, M., Correnti, E., Kamm, K., Kelderman, T., Papetti, L., Rubio-Beltran, E., Vigneri, S., Edvinsson, L., Maassen Van Den Brink, A., & European Headache Federation School of Advanced Studies (EHF-SAS) (2017). Blocking CGRP in migraine patients - a review of pros and cons. The journal of headache and pain, 18(1), 96. https://doi.org/10.1186/s10194-017-0807-1

5. de Vries, T., Villal0n, C. M., & MaassenVanDenBrink, A. (2020). Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacology & therapeutics, 211, 107528. https://doi.org/10.1016/j.pharmthera.2020.107528

Long Name

Calcitonin Gene Related Peptide I

Alternate Names

a-CGRP, alpha-CGRP, CGRP 1, CGRP alpha, CGRP I

Gene Symbol

CALCA

Additional CGRP1 Products

Product Documents for Human CGRP1 ELISA Kit (Colorimetric)

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for Human CGRP1 ELISA Kit (Colorimetric)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. ELISA Kits are guaranteed for 6 months from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.